Polaris Capital Management LLC Sells 5,600 Shares of United Therapeutics Corporation $UTHR

Polaris Capital Management LLC trimmed its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 4.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 122,050 shares of the biotechnology company’s stock after selling 5,600 shares during the quarter. United Therapeutics accounts for 3.4% of Polaris Capital Management LLC’s portfolio, making the stock its 6th largest position. Polaris Capital Management LLC owned about 0.27% of United Therapeutics worth $51,165,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. F m Investments LLC boosted its position in United Therapeutics by 1.3% during the second quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company’s stock worth $741,000 after purchasing an additional 33 shares during the period. HB Wealth Management LLC lifted its stake in shares of United Therapeutics by 2.9% in the second quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company’s stock worth $355,000 after buying an additional 35 shares during the last quarter. WealthCollab LLC boosted its holdings in shares of United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares during the period. Park Avenue Securities LLC grew its stake in United Therapeutics by 1.7% in the 2nd quarter. Park Avenue Securities LLC now owns 2,353 shares of the biotechnology company’s stock valued at $676,000 after buying an additional 39 shares during the last quarter. Finally, Coldstream Capital Management Inc. grew its stake in United Therapeutics by 2.0% in the 2nd quarter. Coldstream Capital Management Inc. now owns 2,145 shares of the biotechnology company’s stock valued at $616,000 after buying an additional 43 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on UTHR. Wells Fargo & Company raised their price target on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research report on Thursday, October 30th. Morgan Stanley set a $447.00 target price on United Therapeutics in a research note on Wednesday, October 29th. HC Wainwright raised their target price on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Royal Bank Of Canada upped their price target on United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a report on Thursday, October 30th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $575.00 price objective on shares of United Therapeutics in a research report on Wednesday, November 19th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $509.50.

Insider Activity at United Therapeutics

In other news, EVP Paul A. Mahon sold 8,300 shares of the firm’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $485.43, for a total value of $4,029,069.00. Following the completion of the sale, the executive vice president directly owned 36,781 shares in the company, valued at approximately $17,854,600.83. This trade represents a 18.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Jan Malcolm sold 50 shares of United Therapeutics stock in a transaction dated Tuesday, December 23rd. The shares were sold at an average price of $512.12, for a total value of $25,606.00. Following the completion of the transaction, the director directly owned 420 shares of the company’s stock, valued at $215,090.40. This represents a 10.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 582,014 shares of company stock valued at $272,706,826. Insiders own 10.30% of the company’s stock.

United Therapeutics Stock Down 0.2%

NASDAQ:UTHR opened at $482.39 on Tuesday. The firm has a market capitalization of $20.77 billion, a PE ratio of 18.28, a price-to-earnings-growth ratio of 2.51 and a beta of 0.84. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $519.99. The firm has a 50-day moving average price of $484.81 and a 200 day moving average price of $404.49.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, beating the consensus estimate of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The company had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. During the same period in the prior year, the company posted $6.39 EPS. The company’s revenue was up 6.8% compared to the same quarter last year. On average, research analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.